-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Protagonist Therapeutics, Maintains $70 Price Target

Benzinga·03/28/2025 13:44:57
Listen to the news
Wedbush analyst Yun Zhong reiterates Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and maintains $70 price target.